外泌体是细胞分泌的纳米级囊泡，是细胞间通信的重要媒介。肌肤衰老的本质在于人体无法维持正常的 细胞更新与稳态，表现为衰老细胞的不断积累、细胞通讯出现紊乱，这与外泌体密不可分。 随着美妆科技不断发展，抗老成分的竞争已从单纯的浓度比拼，升级为靶向性、安全性和作用机制的全 方位较量。 在众多的抗老成分中，谷雨新推出的"类人源外泌素HME"以其独特的细胞基因级抗老机制引起了广泛 关注，它与传统热门成分玻色因和A醇相比，究竟有何优势？ 01 三大抗老成分机理对比 谷雨类人源外泌素HME：细胞基因级的精准抗老 类人源外泌素HME是谷雨利用独家人工外泌体专利技术研发的突破性抗老原料，它代表着抗老护肤的 前沿答案。 这一成分的创新之处在于，它通过体外仿生手段合成高度类人源的人工外泌体，精准模拟天然人源外泌 体的磷脂双分子层结构。 类人源外泌素HME的创新在于，它负载了miRNA、siRNA等人源外泌体中的标志性基因级核心功效成 分，同时镶嵌靶向肽，可实现对细胞的精准调控。 这意味着它不是简单的"化学作用"，而是直接向细胞释放"生物指令"，从源头上干预衰老进程。 玻色因：温和修护的保守派 玻色因作为一种传统抗老成分，其核心功效源 ...

Project Overview - The project is named "Annual Production of 855 Tons of Green Active Raw Materials" and is initiated by Shandong Yunluo Biotechnology Co., Ltd. [2] - The total estimated investment for the project is 100 million yuan, with 7.5% allocated for environmental protection, amounting to 7.5 million yuan [2]. - The construction period is planned for one year, and the project will utilize existing factory buildings while acquiring new production equipment [2]. Production Capacity - Upon reaching full production capacity, the project is expected to produce 1 ton of probiotics, 5 tons of ergothioneine, 126 tons of ectoine, 250 tons of hydroxypropyl tetrahydropyran triol (Bosein), and 473 tons of gluconic acid annually [2][3]. - The products will be sold externally and adhere to the company's quality standards [3]. Company Background - Shandong Yunluo Biotechnology Co., Ltd. is a wholly-owned subsidiary of Shanghai Yunluo Biotechnology Co., Ltd. [3]. - The company focuses on synthetic biology, specializing in enzyme gene mining, directed enzyme modification, cell factory construction, biological fermentation, and enzyme catalysis [3]. Industry Event - The Fourth Synthetic Biology and Green Bio-Manufacturing Conference (SynBioCon 2025) will be held from August 20-22 in Ningbo, Zhejiang [5]. - The conference will focus on the integration of AI and biological manufacturing, as well as the industrialization progress and opportunities in green chemistry, new materials, future food, and agriculture [5]. - Various stakeholders, including international enterprises, industry experts, and government representatives, will participate to explore trends in biological manufacturing and innovation [5].

Core Viewpoint - Nengte Technology (002102.SZ) is experiencing explosive growth in performance, with a projected net profit of 330 million to 380 million yuan for the first half of 2025, representing a year-on-year increase of 480.15% to 568.05% [1][2] Financial Performance - The expected net profit for the first half of 2025 is significantly higher than the previous year's 56.88 million yuan, indicating a growth rate of 480.15% to 568.05% [2] - The net profit after excluding non-recurring gains and losses is projected to be between 400 million and 450 million yuan, a staggering increase of 736.44% to 840.66% compared to last year's 47.82 million yuan [2] - Basic earnings per share are expected to rise from 0.0216 yuan to between 0.1253 and 0.1443 yuan [2] - In Q1 2025, the company achieved an operating income of 2.877 billion yuan, a decrease of 5.38% year-on-year, but the net profit attributable to shareholders increased by 287.20% to 216 million yuan [3] Business Segments - The vitamin E and pharmaceutical intermediates business of the wholly-owned subsidiary Nengte Technology Co., Ltd. is the main contributor to the company's profits, generating over 440 million yuan [2] - The subsidiary has developed into a high-tech enterprise focusing on pharmaceutical intermediates and vitamin E, with key products including montelukast sodium intermediates for asthma treatment and rosuvastatin intermediates for hyperlipidemia treatment [2] Strategic Transformation - The company's performance surge is attributed to its ongoing strategic transformation, which began after the acquisition by Jingzhou City Development Group in 2022 [4] - Since rebranding to Nengte Technology in April 2024, the company has been divesting non-core assets and focusing on pharmaceuticals and vitamin E [4] - In 2024, the company faced a net loss of 489 million yuan due to the underperformance of its plastic trade e-commerce business, which included a goodwill impairment of 591 million yuan [4] Share Buyback and Future Projects - To boost market confidence, the company announced a share buyback plan of 300 million to 500 million yuan, with a maximum buyback price of 3.90 yuan per share [4] - As of the end of Q1, the company had repurchased 98.82 million shares, accounting for 3.75% of the total share capital, using 330 million yuan [4] - The subsidiary is accelerating the construction of new projects, including a 350 million yuan project for an annual production of 100,000 tons of chemical recycling polyester and a 50 million yuan project for an annual production of 100 tons of boswellic acid, which are expected to generate significant net profits upon completion [5]